← All trials
NCT06797817
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2025
- Primary completion
- Sep 1, 2026
- Completion date
- Sep 2, 2027
- First posted
- Jan 28, 2025
- Last posted
- Feb 10, 2025
- Enrollment
- 156
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Universidad de AlmeriaLead sponsor
- Universidad de AlmeriaSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.